复星医药：注射用乳糖酸红霉素药品注册申请获受理

Core Viewpoint - Fosun Pharma's subsidiary, Suzhou Erye Pharmaceutical Co., Ltd., has recently had its drug registration application for injectable lactulose erythromycin accepted by the National Medical Products Administration [1] Group 1: Company Developments - The cumulative R&D investment for the injectable lactulose erythromycin by the group is approximately RMB 6.33 million (unaudited) as of December 2025 [1] - The sales revenue for injectable lactulose erythromycin in mainland China (excluding Hong Kong, Macau, and Taiwan) is projected to be around RMB 170 million in 2024 according to IQVIA CHPA data [1]